Cytonics

Growth Stage

Developing diagnostics and therapeutics for osteoarthritis

Overview

Platform

Dealmaker Securities

Start Date

01/03/2023

Close Date

04/01/2023

Min. Goal

$25,000

Max. Goal

$1,951,220

Min. Investment

$1,000

Security Type

Equity - Preferred

Series

Series C

Funding Type

RegCF

Price Per Share

$2.30

Pre-Money Valuation

$58,915,995

Location

Jupiter, Florida

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Low

Capital Intensity

High

Business Type

Growth

Cytonics, with a valuation of $58.9 million, is raising funds on Dealmaker Securities. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. The company has a strong IP portfolio with 22 issued US and international patents. Gaetano Scuderi founded Cytonics Corporation in July 2006. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.9 million. The campaign proceeds will be used for GMP manufacturing of CYT-108, phase 1 human clinical trial, and working capital.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$307,500

$591,056

COGS

$2,205,358

$503,906

Tax

$0

$0

 

 

Net Income

$-22,544,189

$-995,850

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$967,757

$537,354

Accounts Receivable

$341,193

$283,676

Total Assets

$1,756,758

$1,466,746

Short-Term Debt

$554,929

$2,400,661

Long-Term Debt

$0

$107,502

Total Liabilities

$554,929

$2,508,163

Financials as of: 01/03/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Cytonics 04/01/2023 Dealmaker Securities $58,915,995 $0 Equity - Preferred Active RegCF
Cytonics 10/14/2022 SeedInvest $58,915,996 $2,633,766 Equity - Preferred Funded RegCF / RegD 506(c)
Cytonics 04/30/2021 SeedInvest $46,701,000 $4,667,638 Equity - Preferred Funded RegA+
Cytonics 05/18/2019 SeedInvest $32,400,000 $494,344 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Cytonics on Dealmaker Securities 2023
$
Platform: Dealmaker Securities
Security Type: Equity - Preferred
Valuation: $58,915,995
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow Cytonics on Dealmaker Securities 2023
View on Dealmaker Securities